On 21 August 2019, orphan designation EU/3/19/2199 was granted by the European Commission to Ziopharm Oncology Limited, Ireland, for veledimex for the treatment of glioma.
Please note that this product was withdrawn from the Union Register of orphan medicinal products in March 2022 on request of the Sponsor.
Treatment of glioma
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: